According to the FDA prescribing information for Zepbound, in the SURMOUNT-1 trial, cholelithiasis was reported in 2.5% of patients receiving tirzepatide compared to 1.0% of patients on placebo
If your appetite is small, eat protein first, then the vegetables, and finally the complex carbs
GLP-1 secretion assay data and qRT-PCR data were evaluated for statistical significance by Students paired t test or by ANOVA analysis followed by a Bonferroni post test, as indicated in the figure legends
These treatments work as a GLP-1 agonist by: Increasing insulin release Lowering glucagon levels Delaying gastric emptying Reducing appetite Please note that these treatments are not suitable for individuals with type 1 diabetes
For broader context on related conditions and treatment categories, you can browse the Type 2 Diabetes Hub, Diabetes Hub, Diabetes Articles, Type 2 Diabetes Category, and Diabetes Products
Our systematic review and meta-analysis had some limitations that must be noted